There are three kinds of vaccines: inactivated vaccine and recombinant protein H vaccine. The approval of the new vaccine also represents the vaccination of H vaccine, recombinant protein vaccine and COVID-19 vaccine in China. It has a very positive effect on preventing epidemic situation. According to the experimental data, in the process of use, we can choose to complete the vaccination by orally inhaling the vaccine into small particles, thus helping the human body to improve its protection ability. Clinically, compared with the previous vaccine, the new vaccine has fewer side effects, higher safety and stronger immune effect.
Inhalation vaccine
From June 5438+1October 65438+March, 2022, China COVID-19 made new progress in vaccine research and development. It is reported that Amano has conducted clinical trials of inhalation vaccine in Latin America, Southeast Asia and even the whole world. Compared with vaccination like me, in order to get approval faster, COVID-19 vaccine can stimulate more effective antibodies and help people improve their self-protection ability. This vaccine is very different from previous vaccines. The usefulness of the model can be preserved in the form of freeze-dried powder, and it can be stored and transported stably at 2-8 degrees Celsius, which is helpful to spread the vaccine widely and improve the probability of obtaining the vaccine.
When is it not widely vaccinated?
If a person suffers from diabetes, hypertension, heart disease and other potential diseases, it is not suitable for re-inoculation, that is, inhalation vaccine and non-injection vaccine, and it is necessary to wait for a period of comprehensive notification. At present, China's prevention of COVID-19 is at a critical stage. The development of vaccines in COVID-19 is a continuous process. After the completion of the third phase of clinical trials and relevant departments, we have done a good job in quality control and safety, and continued to strengthen the prevention of COVID-19 infection and technical development.